Literature DB >> 9125444

Extracellular levels of glutamate and aspartate in the entopeduncular nucleus of the rat determined by microdialysis: regulation by striatal dopamine D2 receptors via the indirect striatal output pathway?

C S Biggs1, L J Fowler, P S Whitton, M S Starr.   

Abstract

This study used intracerebral microdialysis to monitor the outputs of excitatory amino acids in the entopeduncular nucleus (EPN) of conscious or halothane-anaesthetized rats, in an attempt to obtain direct biochemical evidence for the theory that neuronal inputs to the EPN by the indirect striatal output pathway are glutamatergic and regulated primarily by dopamine D2 receptors in the striatum. In dopamine-intact animals, both glutamate and asparate were readily detectable in EPN dialysates. Recoveries of both amino acids were increased bilaterally by local perfusion with veratridine (100 microM, given under halothane anaesthesia), pretreatment with reserpine (4 mg/kg, i.p., 24 h beforehand), unilateral pretreatment of the medial forebrain bundle with 6-OHDA (8 microg/4 microl), and by the systemic (1 mg/kg, i.p.) or bilateral intrastriatal (7 microg/0.5 microl under halothane anaesthesia) administration of the dopamine D2 receptor antagonist haloperidol, but not raclopride (2 mg/kg, i.p.). The dopamine D1 receptor antagonist SCH 23390 was ineffective both systemically (0.25 mg/kg, i.p.) and intrastriatally (0.125 microg/0.5 microl/side), as also were control intrastriatal injections of saline (0.5 microl/side). By contrast, the dopamine D2/3 receptor agonist quinpirole (4 mg/kg, i.p.) lowered the outputs of glutamate and aspartate in the EPN of reserpine-treated and normal individuals, whilst the dopamine D1 receptor agonist SKF 38393 (30 mg/kg, i.p.) was inactive; however, both drugs caused behavioural arousal. The dopamine D2/3 receptor agonist RU 24213 reversed reserpine-induced akinesia, yet paradoxically increased glutamate (not aspartate) output in the EPN still further. The combination of benserazide (30 mg/kg, i.p.) and L-DOPA (50 mg/kg, i.p.) evoked intense contraversive circling in unilaterally 6-OHDA-lesioned rats, together with a drop in EPN glutamate (but not aspartate) output in the intact but not lesioned hemisphere. These results offer biochemical support for the hypothesis that excitatory neurones innervating the EPN via the indirect striatal output pathway, may utilise glutamate and/or aspartate as their neurotransmitter. They further endorse the view that the EPN receives information from striatal D2 and not D1 receptors via excitatory synapses, which become hyperactive following dopamine depletion or inactivation, and which are subject to control by the contralateral as well as by the ipsilateral hemisphere. The results obtained with RU 24213 and L-DOPA, however, indicate that dopaminergic behaviours can also occur independently of glutamate or aspartate release in the EPN.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125444     DOI: 10.1016/s0006-8993(97)00033-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Glutaraldehyde cross-linked glutamate oxidase coated microelectrode arrays: selectivity and resting levels of glutamate in the CNS.

Authors:  Jason J Burmeister; Verda A Davis; Jorge E Quintero; Francois Pomerleau; Peter Huettl; Greg A Gerhardt
Journal:  ACS Chem Neurosci       Date:  2013-05-09       Impact factor: 4.418

2.  Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.

Authors:  M Broadstock; P J Austin; M J Betts; S Duty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats.

Authors:  M Miele; M A Mura; P Enrico; G Esposito; P A Serra; R Migheli; D Zangani; E Miele; M S Desole
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex.

Authors:  Erin R Hascup; Kevin N Hascup; Michelle Stephens; Francois Pomerleau; Peter Huettl; Alain Gratton; Greg A Gerhardt
Journal:  J Neurochem       Date:  2010-11-19       Impact factor: 5.372

Review 5.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 6.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Ethanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis.

Authors:  Sarah Fliegel; Ines Brand; Rainer Spanagel; Hamid R Noori
Journal:  In Silico Pharmacol       Date:  2013-05-17

Review 8.  Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective.

Authors:  Rajashree Banerjee; Arushi Rai; Shreyas M Iyer; Sonia Narwal; Meghana Tare
Journal:  Animal Model Exp Med       Date:  2022-01-27

Review 9.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.